LivaNova (NASDAQ:LIVN) Upgraded by KeyCorp to “Strong-Buy” Rating

KeyCorp upgraded shares of LivaNova (NASDAQ:LIVN) to a strong-buy rating in a report issued on Thursday,Zacks.com reports.

Several other brokerages have also recently commented on LIVN. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Barclays increased their price target on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Mizuho lifted their price objective on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $65.63.

LivaNova Price Performance

Shares of LIVN stock opened at $62.82 on Thursday. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -15.70 and a beta of 1.02. LivaNova has a 12 month low of $32.48 and a 12 month high of $65.57. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The stock has a 50-day moving average price of $57.31 and a 200 day moving average price of $52.21.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL bought a new stake in shares of LivaNova in the 3rd quarter valued at $1,746,000. CIBC Bancorp USA Inc. bought a new position in LivaNova during the third quarter worth about $304,000. Oberweis Asset Management Inc. acquired a new position in LivaNova in the third quarter valued at about $9,743,000. Shelton Capital Management bought a new stake in shares of LivaNova in the third quarter worth about $325,000. Finally, Quarry LP acquired a new stake in shares of LivaNova during the third quarter worth about $36,000. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.